FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying
Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.